BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026

Financings

  • Financings
    • Grant
    • PIPE (private investment of public equity)
    • Private
    • Public
Home » Topics » Financings
  • June 11, 2026

    Ethyreal Bio launches with focus on thyroid diseases

    Ethyreal Bio Inc. has launched with $101 million in financing and a focus on developing precision therapies for thyroid diseases with high unmet need.
  • June 10, 2026

    Financings for June 10, 2026

    Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Antogen, Cerus, City, Corvus, Dicot, Eloxx, Ideaya, Idorsia, Shattuck, Starton.
  • Virtual ipo word with stock graph and arrow
    June 10, 2026
    By Jennifer Boggs

    Parabilis takes top spot, pricing largest biopharma IPO at $670M

    Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced its upsized IPO of 3.5 million shares at $20 apiece for gross proceeds of $670 million, an amount that could rise to $770 million should underwriters exercise their full 5-million-share overallotment option.
Read More

Authors

  • Michael Fitzhugh
  • Tamra Sami
  • Randy Osborne
  • Annette Boyle
  • Nuala Moran
  • Lee Landenberger
More Authors

Pages

  • Med-tech follow-on offerings in 2026
  • Other financings of public med-tech companies in 2026
  • Private med-tech company financings in 2026
  • Med-tech IPOs in 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing